DLC & DPAC submitted comments to the Centers for Medicare & Medicaid Services regarding the agency's proposed rule on Medicare CGM coverage. We welcome a shorter, more predictable pathway to Medicare coverage for all U.S. Food and Drug Administration-approved CGM products but have grave concerns regarding proposed reimbursement changes that could disrupt CGM access for more than 100,000 seniors. Read the comments in full here.
